MedTrace Logo

MOD-4023 Study in Healthy Male Volunteers

NCT01060722 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-09-30

No results posted yet for this study

Summary

This study aims to examine the safety, tolerability and pharmacokinetics of a long-lasting Human Growth Hormone (MOD-4023) in healthy volunteers after a single subcutaneous injection at escalating doses.

Conditions

  • Healthy

Interventions

DRUG

MOD-4023 (long lasting hGH)

Single subcutaneous dose of MOD-4023

DRUG

Placebo

Single subcutaneous dose of placebo material

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    collaborator OTHER_GOV

  • OPKO Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Jacob Atsmon, M.D. · Tel-Aviv Sourasky Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01060722 on ClinicalTrials.gov